Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Adagio Medical reports zero sales and $3.1m cash while FDA weighs ablation device

The cardiac ablation company's US launch hinges on a pending regulatory decision with no disclosed date, as its board reviews options and it consolidates its shares.

16 Nov 2026 · Adagio Medical Holdings, Inc. ADGM · Company news

Adagio Medical Holdings has no commercial revenue to show for the third quarter of 2026, and its only US route to market, a regulatory filing for its vCLAS system to treat ventricular tachycardia, is still with the Food and Drug Administration. The company gave the update with its results on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Adagio Medical Holdings, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →